AGC– tag –
-
AGC Biologics Commits Half of New Yokohama Biomanufacturing Plant to Major Long-Term Deal
Megaproject Japan Overview AGC Biologics has secured a significant multi-million dollar, long-term commercial manufacturing contract with an undisclosed pharmaceutical firm for its new Yokohama facility, set to open in 2027. This landmar... -
AGC Biologics Secures Landmark Multi-Hundred-Million-Dollar Deal for Yokohama Facility, Cementing Japan’s Biologics Manufacturing Leadership
AGC Biologics Japan Overview AGC Biologics has secured a multi-year, multi-hundred-million-dollar commercial manufacturing agreement for its new Yokohama facility, slated to open in 2027. This landmark deal dedicates approximately half o... -
Japan Prioritizes Quality in ‘China Plus One’ CDMO Strategy with Over $4 Billion Investment by FUJIFILM Diosynth and Others
BioProcess International USA Overview A BioProcess International article analyzes the 'China Plus One' strategy and biomanufacturing capacity in the APAC region. FUJIFILM Diosynth Biotechnologies has committed over $4 billion to global e... -
Global Pharma and Biotech Firms Intensify Investment in Biologics Contract Manufacturing Market, openPR.com Reports
openPR.com USA Overview Global pharmaceutical and biotechnology companies are significantly increasing their investments in the biologics contract manufacturing (CDMO) market, as reported by openPR.com. FUJIFILM Diosynth Biotechnologies ... -
Market Report: Global Single-Use Bioreactor Market to Surge, Thermo Fisher and AGC Biologics Expand Capacity
GlobeNewswire Global Overview This article summarizes the market research report "Global Single-use Bioreactors Market Forecast to Surge from USD 3.61 Billion in 2025 to USD 15.11 Billion by 2034." The global single-use bioreactors marke... -
REPROCELL Enhances 3D Cell Culture Product Portfolio with Alvetex® & EZSPHERE™ to Advance Drug Discovery Translational Research
REPROCELL Japan Overview REPROCELL is fortifying its diverse 3D cell culture product lines, including Alvetex® 3D Cell Culture Systems and the Alvetex® Advanced Tissue Bioengineering System, to provide biologically relevant, reproducible... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
Denmark Fortifies Biomanufacturing Leadership with $239M AGC Biologics Investment
GeneOnline デンマーク Overview Denmark is rapidly consolidating its position as a global biomanufacturing powerhouse, attracting substantial investment in its advanced infrastructure. AGC Biologics has committed $239 million to significa... -
Strategic CDMO Partnerships Accelerate in Cell and Gene Therapy Market to Tackle Manufacturing and Cost Challenges
Contract Pharma USA Overview The burgeoning cell and gene therapy (CGT) market is increasingly relying on strategic CDMO partnerships to navigate complex manufacturing and cost challenges. Sponsors are actively seeking CDMOs with special... -
AGC Biologics & Asimov Revolutionize Viral Vector Manufacturing with Single-Plasmid Lentiviral Edge Packaging Cell Line License
MetaphysicalCells Unknown Overview AGC Biologics and Asimov have licensed Asimov's pre-engineered Lentiviral (LV) Edge Packaging cell line, poised to revolutionize viral vector manufacturing. AGC Biologics' Milan facility can now produce...
